Semisynthetic macrolide antibiotics of the azalide series

Details Semisynthetic macrolide antibiotics of the azalide series Semisynthetic macrolide antibiotics of the azalide series

2003-12-10

2008-03-11

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S007400

Reexamination Certificate

active

07342000

ABSTRACT:
The invention relates to N″-substituted 9a-N-(N′-carbamoyl-γ-aminopropyl), 9a-N-(N′-thiocarbamoyl-γ-aminopropyl), 9a-N-[N′-β-cyanoethyl)-N′-carbamoyl-γ-aminopropyl] and 9a-N-[N′-β-cyanoethyl)-N′-thiocarbamoyl-γ-am inopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semi-synthetic macrolide antibiotics of the azalide series, of the general formula 1, wherein R represents H or cladinosyl moiety, R1represents H or β-cyanoethyl moiety, R2represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyl)phenyl, 3-phenylpropyl, β-phenylethyl, ethoxycarbonyl-methyl, 1-(1-naphtyl)ethyl, 3,4,5-trimethoxyphenyl and 2,4-dichlorophenyl group, and X represents O and S, and their acceptable addition salts thereof with inorganic or organic acids, to the process for preparation of their pharmaceutical compositions as well as the use their compositions in the treatment of bacterial infections.

REFERENCES:
patent: 4328334 (1982-05-01), Kobrehel et al.
patent: 4474768 (1984-10-01), Bright
patent: 4492688 (1985-01-01), Bright
patent: 6852702 (2005-02-01), Kujundzic et al.
patent: 6872707 (2005-03-01), Marusic-Istuk et al.
patent: 892397 (1982-03-01), None
patent: 0 132 944 (1986-12-01), None
patent: 0 316 128 (1989-05-01), None
patent: 0 657 464 (1995-06-01), None
patent: 2 473 525 (1981-07-01), None
patent: WO 97/35590 (1997-10-01), None
patent: WO 02/068438 (2002-09-01), None
patent: WO 2004/043984 (2004-05-01), None
patent: WO 2004/043985 (2004-05-01), None
Puri, S.K., and Singh, Naresh. 2000. Azithromycin: Antimalarial Profile against Blood- and Sporozoite-Induced Infections in Mice and Monkeys.Experimental Parasitology94:8-14.
Sadiq, S.T., et al. 1995. Effects of azithromycin on malariometric indices in The Gambia.The Lancet346:881-882.
Kobrehel, Gabrijela, et al. 1993. 9a, 11-Cyclic Carbamates of 15-Membered Azalides.The Journal of Antibiotics46(8):1239-1245.
Luger, Peter, and Maier, Roland. 1979. Molecular structure of 9-deoxy-11-deoxy-9-11-(imino(2-(2-methoxyethoxy)ethylidene)oxy)-(9S)-erythromycin, a new erythromycin derivative.Journal of Crystal and Molecular Structure9(6):329-338.
Egan, Richard S., et al. 1974. Configuration of 9-Imino Derivatives of Erythromycin.J. Org. Chem.39(17):2492-2494.
Kurath, P., et al. 1971. Acid Degradation of Erythromycin A and Erythromycin B.Experientia27(4):362.
Djokic, Slobodan, and Tamburasev, Zrinka. 1967. Erythromycin Study: 9-amino-3-O-cladinosyl-5-0-desoaminyl-6.11,12-tryhydroxy-2,4,6,8,10,12-hexamethylpentadecame-13-olide.Tetrahedron Letters17:1645-1647.
McGuire, J.M. et al. 1952. “Ilotycin,” A New Antibiotic.Antibiotics and ChemotherapyII(6): 281-283.

Affiliated with

Also associated with

Rating

Semisynthetic macrolide antibiotics of the azalide series does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Semisynthetic macrolide antibiotics of the azalide series, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Semisynthetic macrolide antibiotics of the azalide series will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3973771